Wednesday, April 24, 2019 8:55:02 AM
Beleave Announces Initial Cannabis Oil Sales After Receiving Health Canada Authorization Derivatives with Higher-Margins Increasing Growth and Revenues
Toronto, Ontario— April 8, 2019 – Beleave Inc. (CSE: BE) (OTCQX: BLEVF) ("Beleave" or the "Company") is pleased to announce that its wholly-owned subsidiary Beleave Kannabis Corp has commenced sales of cannabis oil products at its licensed facility in Hamilton, Ontario.
Beleave has completed its first wholesale transfer of two bulk lots of cannabis oil to another standard processor license holder, as well as having begun cannabis oil product sales to medicinal patients through its online store https://shop.beleave.com. The Company received authorization from Health Canada to sell cannabis oil products in January 2019.
“We've been looking forward to sharing these efforts with our patients and the entire Beleave community. I'm happy to say that the time has finally come,” said Roger Ferreira, Chief Science Officer at Beleave. “Our whole team has been working hard to ensure we're delivering on our commitment to produce high-quality products that we can all be proud of. We continue to invest in our research and development pipeline in anticipation of future opportunities in the Canadian cannabis derivatives market.”
Current product offerings available to medicinal patients include a blended and balanced THC/CBD cannabis oil. These high-quality and pure cannabis oil products are being offered to patients in convenient and easy-to-use 30 mL bottles with an applicator – allowing for precise dosing control by the patient. MCT, a non-allergenic, flavourless and odourless oil widely-used for pharmaceutical applications, will be used as the carrier oil for Beleave's cannabis oil products to assist in the timely delivery and absorption of THC and CBD.
Cannabis oil production is already underway at Beleave's industrial extraction laboratory using proprietary (patent-pending) methods. This process involves the activation, extraction and purification of THC and CBD using only potable components, without using any organic solvents. In addition to producing oils for Beleave's own medicinal patients, the Company is actively engaged in contract negotiations to offer the same extraction, processing, packaging and distribution services to other micro and standard processor licensed companies.
“We are very excited and proud of our scientific research team and the quality of the work they're producing,” said Bill Panagiotakopoulos, Chief Executive Officer at Beleave. “In conjunction with our dried flower products, we feel our company's success will also rely on the production and processing of oils and derivatives for the adult recreational market, antici- pated for later this year. This is another great milestone for Beleave.”
Patent applications submitted for the Company's processes include a regularly submitted United States patent application (U.S. Patent Application 16/201,547), as well as a Patent Cooperation Treaty (PCT) and International Application (PCT Patent Application PCT/- CA2018/051508).
Recent BE News
- Bloom Energy and Quanta Computer Forge Transformative Partnership to Power Silicon Valley's AI Revolution • Business Wire • 04/29/2024 08:01:00 PM
- Bloom Energy to Announce First Quarter 2024 Financial Results on May 9, 2024 • Business Wire • 04/25/2024 08:01:00 PM
- Bloom Energy Appoints Daniel Berenbaum as Chief Financial Officer • Business Wire • 04/17/2024 11:30:00 AM
- Tesla Resolves Autopilot Lawsuit, JPMorgan Unveils Potential CEO Successors, and More • IH Market News • 04/09/2024 10:39:30 AM
- Bloom Energy to Receive up to $75 million in Federal Tax Credits for Fremont Manufacturing Plant • Business Wire • 04/08/2024 08:03:00 PM
- Bloom Energy Inc. Signs Agreements with Shell to Investigate Opportunities for Innovative Large-Scale, Renewable Hydrogen Energy Projects • Business Wire • 03/06/2024 02:02:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/15/2024 09:09:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:02:34 PM
- Bloom Energy Reports Fourth Quarter and Full Year 2023 Financial Results with Record Full Year Revenues • Business Wire • 02/15/2024 09:02:00 PM
- Bloom Energy Introduces Load Following Capability to Enable Customers and Utilities to Meet Variable Electricity Load and Demand • Business Wire • 02/12/2024 02:01:00 PM
- Bloom Energy to Announce Fourth Quarter and Fiscal Year 2023 Financial Results on February 15, 2024 • Business Wire • 01/31/2024 09:04:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:00:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/16/2024 09:48:26 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 01:00:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 01:59:39 PM
- Bloom Energy and SK ecoplant Collaborate on a Major Hydrogen Project to be Developed by Korea Southern Power Co., Ltd • Business Wire • 12/27/2023 10:33:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 02:04:38 PM
- Bloom Energy and SK ecoplant Announce 500 MW Sales Agreement Strengthening Existing Partnership • Business Wire • 12/22/2023 02:00:00 PM
- SoCalGas and Bloom Energy Powering Caltech with Innovative Campus Hydrogen Project • PR Newswire (US) • 12/14/2023 11:50:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/15/2023 09:29:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:08:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:05:46 PM
- Bloom Energy Reports Record Revenue in Third Quarter 2023 Financial Results • Business Wire • 11/08/2023 09:05:00 PM
- Bloom Energy to Announce Third Quarter 2023 Financial Results on November 8, 2023 • Business Wire • 10/25/2023 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/17/2023 11:36:36 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM